
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QN-302 is a small molecule G-Quadruplex (G4)-selective transcription inhibitor in Phase 1 clinical development for the treatment of G4-expressing solid tumors, such as pancreatic cancer (PDAC), prostate cancer, sarcomas, and others.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qualigen Therapeutics Initiates Good Laboratory Practice (GLP) Toxicology Studies on QN-302
Details : QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 24, 2023
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QN-302 (formerly SOP1812) is a G4 selective transcription inhibitor. QN-302 is a small molecule drug candidate with superior efficacy and activity against pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 10, 2023
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The licensed technology comprises lead compound QN-302 (formerly SOP1812) and back-up compounds that target regulatory regions of cancer genes that down-regulate gene expression in multiple cancer pathways.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : F3-8-60
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : F3-8-60, pan-RAS inhibitor with efficacy in malignant peripheral nerve sheath tumors and pancreatic cancer,demonstrated the ability to inhibit the metastasis of a malignant peripheral nerve sheath tumor cell line.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2022
Lead Product(s) : F3-8-60
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : The Division of Cancer Treatment and Diagnosis
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
Details : QN-302 compound is a small molecule selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells; such binding could, by stabilizing the G4s against “unwinding,” help inhibit cancer cell proliferation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 14, 2022
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-247
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Qualigen Therapeutics Reports Positive QN-247 Readout in Triple Negative Breast Cancer in Vivo Model
Details : QN-247 demonstrated a robust efficacy signal and showed no adverse events or toxicities at the tested therapeutic dose in an animal model for triple negative breast cancer (TNBC), a rare, highly aggressive and difficult to treat form of breast cancer.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 01, 2022
Lead Product(s) : QN-247
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Hande Sciences
Deal Size : Undisclosed
Deal Type : Partnership
Details : QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for Pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need, such as Prostate Cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 06, 2022
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Hande Sciences
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QN-302 is Qualigen’s G-quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for PDAC, in addition to other tumors of high unmet clinical need.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : QN-302
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Qualigen’s RAS-F, is a family of small molecules designed to prevent mutated RAS gene proteins from binding to their effector proteins. Exclusively in-licensed from UofL, compounds from this discovery engine have been shown to impact tumor growth in mu...
Product Name : RAS-F
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 26, 2022
